‌

US Patent 8313943 Genetically modified human natural killer cell lines

Patent 8313943 was granted and assigned to Fox Chase Cancer Center (company) on November, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Current Assignee

Fox Chase Cancer Center (company)

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Kerry S. Campbell0

Date of Patent

November 20, 2012

0

Patent Application Number

125642830

Date Filed

September 22, 2009

0

Patent Citations Received

US Patent 12109238 Chimeric antigen receptor-modified NK-92 cells

0

US Patent 11857620 Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus

0

US Patent 11975027 Tumoricidal and antimicrobial compositions and methods

0

US Patent 11992504 Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment

0

US Patent 12064450 Tumoricidal and antimicrobial compositions and methods

0

US Patent 11684668 Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence

0

US Patent 11753625 Modified NK-92 haNK003 cells for the clinic

US Patent 11788059 Modified NK-92 cells for treating cancer

Patent Primary Examiner

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8313943 Genetically modified human natural killer cell lines

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.